Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-06
2006-06-06
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S588000, C540S589000, C540S590000, C540S591000, C540S592000
Reexamination Certificate
active
07056911
ABSTRACT:
The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention and particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection such as pneumocystis pneumonia, toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.
REFERENCES:
patent: 4962200 (1990-10-01), Kihara et al.
patent: 372675 (1963-12-01), None
patent: 376 920 (1964-04-01), None
patent: 437 974 (1926-12-01), None
patent: 842 943 (1952-07-01), None
patent: 549352 (1993-06-01), None
patent: 818 269 (1959-08-01), None
patent: 822592 (1959-10-01), None
patent: 8-119920 (1996-05-01), None
Marangos, Paul J.; Post, Robert M.; Patel, Jitendra; Zander, Karl; Parma, Alexandra; Weiss, Susan, European Journal of Pharmacology, 93(3-4), 175-82 (English) 1983.
Andreani, A.; Rambaldi, M.; Locatelli, A.; Aresca, P.; Bossa, R.; Galatulas, I., European Journal of Medicinal Chemistry, 26(1), 113-16 (English) 1991.
“The Condensed Chemical Dictionary, Ninth Ed.” Gesser G. Hawley, Van Nostrand, New York, 1977 , pp. 27 and 650.
Garforth, Jacqueline; Yin, Hong; McKie, James H.; Douglas, Kenneth T.; Fairlamb, Alan H., Journal of Enzyme Inhibition, 12(3), 161-173 (English) 1997.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 4ed, Part 1”, John Wiley & Sons, 1979, pp. 321-323 and 468-469.
RM Corwin and Julie Nahm, University of Missouri College of Veterinary Medicine, 1997..
S. Schurmann et al., “Twice-weekly Pyrimethamine-sulfadoxine Effectively PreventsPneumocystis carinilPneumionia Relapse andToxoplasmic encephalitisin Patients with AIDS,” J. of Infection (2001) 42, 8-15.
D. Podzamezer, M.D., “intermittent Trimethoprisim-Sulfamethoxzole Compared with Dapsone-Pyrimethamine for the Simultaneous Primary Prophylaxis ofPneumocystis pneumoniaand Toxoplasmosis in Patients Infected with HIV,” Ann. Intern. Med 1995; 122: 755-761.
M.A. Fischl, “Safety and Efficacy of Sulafmethoxazole and Trimethoprim Chemoprophylaxis forPneumocysitis cariniiPneumonia in AIDS,” JAMA 1998, vol. 259, No. 8.
Cremieux et al.,Res. Microbiol., 146:73-83 (1995).
Patent Abstract of Japan, vol. 014, No. 304 (1990).
Database Crossfire Beilstein, Database Accession No. 4457315, XP002206576 (1982).
Database Crossfire Beilstein, Database Accession No. 753200, XP002206577 (1961).
Database Crossfire Beilstein, Database Accession No. 28740, XP002206578 (1957).
S. Schumann et al., “Twice-weekly Pyrimethamine-sulfadoxine Effectively Prevents Pneumocystis carinil Pneumonia Relapse and Toxoplasmic Encephalitis in Patients with AIDS,” J. of Infection (2001) 42, 8-15.
D. Podzamezer, M.D., “Intermittent Trimethoprism-Sulfamethoxzole Compared with Dapsone-Pyrimethamine for the Simultanous Primary Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis in Patients Infected with HIV,” Ann. Intern. Med 1995; 122: 755-761.
M.A. Fischi, “Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for Pneumocysitis carinii Pneumonia in AIDS,” JAMA 1998, vol. 259, No. 8.
Alexander John B.
Corless Peter F.
Dana-Farber Cancer Institute
Edwards & Angell LLP
McKenzie Thomas C.
LandOfFree
Dibenz[B,F]azepine compounds, pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dibenz[B,F]azepine compounds, pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dibenz[B,F]azepine compounds, pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3688611